Risk-based Prostate Cancer Screening: Who and How?

Overview

Journal Curr Urol Rep

Publisher Current Science

Specialty Urology

Date 2013 Mar 28

PMID 23532499

Citations 10

Authors

Allison S Glass

K Clint Cary

Matthew R Cooperberg

Affiliations

Soon will be listed here.

Abstract

The purpose of this review is to identify clinical risk factors for prostate cancer and to assess the utility and limitations of our current tools for prostate cancer screening. Prostate-specific antigen is the single most important factor for identifying men at increased risk of prostate cancer but is best assessed in the context of other clinical factors; increasing age, race, and family history are well-established risk factors for the diagnosis of prostate cancer. In addition to clinical risk calculators, novel tools such as multiparametric imaging, serum or urinary biomarkers, and genetic profiling show promise in improving prostate cancer diagnosis and characterization. Optimal use of existing and future tools will help alleviate the problems of overdiagnosis and overtreatment of low-risk prostate cancer without reversing the substantial mortality declines that have been achieved in the screening era.

Citing Articles

MR Molecular Imaging of Extradomain-B Fibronectin for Assessing Progression and Therapy Resistance of Prostate Cancer.

Vaidya A, Shankardass A, Buford M, Hall R, Qiao P, Wang H Chem Biomed Imaging. 2024; 2(8):560-568.

PMID: 39211789 PMC: 11351422. DOI: 10.1021/cbmi.4c00002.

Appetite-regulating hormones-leptin, adiponectin and ghrelin-and the development of prostate cancer: a systematic review and exploratory meta-analysis.

Angel C, Iguacel I, Mullee A, Guha N, Wasson R, McKenna D Prostate Cancer Prostatic Dis. 2019; 23(1):11-23.

PMID: 31147627 DOI: 10.1038/s41391-019-0154-1.

The RNA-binding protein FXR1 modulates prostate cancer progression by regulating FBXO4.

Cao H, Gao R, Yu C, Chen L, Feng Y Funct Integr Genomics. 2019; 19(3):487-496.

PMID: 30746571 DOI: 10.1007/s10142-019-00661-8.

Mitochondrial functions and melatonin: a tour of the reproductive cancers.

de Almeida Chuffa L, Seiva F, Cucielo M, Silveira H, Reiter R, Lupi L Cell Mol Life Sci. 2018; 76(5):837-863.

PMID: 30430198 PMC: 11105419. DOI: 10.1007/s00018-018-2963-0.

Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI.

Ayat N, Qin J, Cheng H, Roelle S, Gao S, Li Y ACS Med Chem Lett. 2018; 9(7):730-735.

PMID: 30034609 PMC: 6047029. DOI: 10.1021/acsmedchemlett.8b00172.

References

Wolf A, Wender R, Etzioni R, Thompson I, DAmico A, Volk R . American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60(2):70-98. DOI: 10.3322/caac.20066. View

Antonelli J, Jones L, Banez L, Thomas J, Anderson K, Taylor L . Exercise and prostate cancer risk in a cohort of veterans undergoing prostate needle biopsy. J Urol. 2009; 182(5):2226-31. DOI: 10.1016/j.juro.2009.07.028. View

Yoshizako T, Wada A, Hayashi T, Uchida K, Sumura M, Uchida N . Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol. 2008; 49(10):1207-13. DOI: 10.1080/02841850802508959. View

Delongchamps N, Beuvon F, Eiss D, Flam T, Muradyan N, Zerbib M . Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer. Prostate Cancer Prostatic Dis. 2011; 14(3):232-7. DOI: 10.1038/pcan.2011.9. View

Fang J, Metter E, Landis P, Chan D, Morrell C, Carter H . Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology. 2001; 58(3):411-6. DOI: 10.1016/s0090-4295(01)01304-8. View

Ankerst D, Groskopf J, Day J, Blase A, Rittenhouse H, Pollock B . Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008; 180(4):1303-8. DOI: 10.1016/j.juro.2008.06.038. View

Nam R, Toi A, Klotz L, Trachtenberg J, Jewett M, Appu S . Assessing individual risk for prostate cancer. J Clin Oncol. 2007; 25(24):3582-8. DOI: 10.1200/JCO.2007.10.6450. View

Roobol M, Steyerberg E, Kranse R, Wolters T, van den Bergh R, Bangma C . A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2009; 57(1):79-85. DOI: 10.1016/j.eururo.2009.08.025. View

Cooperberg M, Broering J, Kantoff P, Carroll P . Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol. 2007; 178(3 Pt 2):S14-9. PMC: 2987559. DOI: 10.1016/j.juro.2007.03.135. View

10.

Ewing C, Ray A, Lange E, Zuhlke K, Robbins C, Tembe W . Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012; 366(2):141-9. PMC: 3779870. DOI: 10.1056/NEJMoa1110000. View

11.

Perner S, Demichelis F, Beroukhim R, Schmidt F, Mosquera J, Setlur S . TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res. 2006; 66(17):8337-41. DOI: 10.1158/0008-5472.CAN-06-1482. View

12.

Kenfield S, Stampfer M, Chan J, Giovannucci E . Smoking and prostate cancer survival and recurrence. JAMA. 2011; 305(24):2548-55. PMC: 3562349. DOI: 10.1001/jama.2011.879. View

13.

Loeb S, Roehl K, Antenor J, Catalona W, Suarez B, Nadler R . Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology. 2006; 67(2):316-20. DOI: 10.1016/j.urology.2005.08.040. View

14.

Schwartz K, Alibhai S, Tomlinson G, Naglie G, Krahn M . Continued undertreatment of older men with localized prostate cancer. Urology. 2003; 62(5):860-5. DOI: 10.1016/s0090-4295(03)00690-3. View

15.

Hsieh K, Albertsen P . Populations at high risk for prostate cancer. Urol Clin North Am. 2003; 30(4):669-76. DOI: 10.1016/s0094-0143(03)00058-2. View

16.

Etzioni R, Gulati R, Tsodikov A, Wever E, Penson D, Heijnsdijk E . The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer. 2012; 118(23):5955-63. PMC: 3424303. DOI: 10.1002/cncr.27594. View

17.

Kawachi M, Bahnson R, Barry M, Busby J, Carroll P, Carter H . NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw. 2010; 8(2):240-62. DOI: 10.6004/jnccn.2010.0016. View

18.

Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J . Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2007; 19(2):175-81. PMC: 3064270. DOI: 10.1007/s10552-007-9083-8. View

19.

Ulmert D, Serio A, OBrien M, Becker C, Eastham J, Scardino P . Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened.... J Clin Oncol. 2008; 26(6):835-41. DOI: 10.1200/JCO.2007.13.1490. View

20.

Loeb S, Roehl K, Helfand B, Kan D, Catalona W . Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?. J Urol. 2009; 183(1):112-6. PMC: 3140466. DOI: 10.1016/j.juro.2009.08.156. View